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Abstract
Tumors of the central nervous system represent a major source of cancer-related deaths, with medulloblastoma and
glioblastoma being the most common malignant brain tumors in children and adults respectively. While significant
advances in treatment have been made, with the 5-year survival rate for medulloblastoma at 70–80%, treating patients
under 3 years of age still poses a problem due to the deleterious effects of radiation on the developing brain, and the
median survival for patients with glioblastoma is only 15 months. The transcription factor, STAT3, has been found
constitutively activated in a wide variety of cancers and in recent years it has become an attractive therapeutic target. We
designed a non-peptide small molecule STAT3 inhibitor, LLL12, using structure-based design. LLL12 was able to inhibit
STAT3 phosphorylation, decrease cell viability and induce apoptosis in medulloblastoma and glioblastoma cell lines with
elevated levels of p-STAT3 (Y705). IC50 values for LLL12 were found to be between 1.07 mM and 5.98 mM in the five cell lines
expressing phosphorylated STAT3. STAT3 target genes were found to be downregulated and a decrease in STAT3 DNA
binding was observed following LLL12 treatment, indicating that LLL12 is an effective STAT3 inhibitor. LLL12 was also able
to inhibit colony formation, wound healing and decreased IL-6 and LIF secretion. Our results suggest that LLL12 is a potent
STAT3 inhibitor and that it may be a potential therapeutic treatment for medulloblastoma and glioblastoma.
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Introduction
While tumors of the central nervous system account for only a
small percentage of cancer diagnoses, they represent a major
source of cancer-related deaths. Almost 13,000 deaths occur
annually in the US from primary malignant brain and CNS
tumors [1]. The most common pediatric and adult CNS tumors
are medulloblastoma and glioblastoma respectively [2]. Medullo-
blastoma accounts for approximately 20% of all pediatric CNS
tumors, making it the most common malignant brain tumor in
children [1]. Medulloblastomas are typically very radiosensitive
tumors and the current standard for treating average risk patients
is surgical resection followed by radiation and chemotherapy.
However, in patients younger than 3 years of age, radiation is
often avoided if possible due to the highly deleterious effects seen
on the developing brain [3].
Glioblastoma is the most common brain tumor in adults [4] but
8–9% of cases are diagnosed in children [5]. The tumor is difficult
to treat due to its invasive, aggressive and diffuse nature and the
typical course of treatment is surgical resection, followed by
radiation and chemotherapy [6,7]. However, even with treatment,
the median survival period is only 15 months [7]. The difficulty
experienced trying to treat these tumors, combined with the highly
toxic effects of radiation on the brains of young children, make
alternative therapies highly desirable.
Signal transducer and activator of transcription 3 (STAT3) is a
member of the STAT family of transcription factors which
activates a variety of genes such as c-myc, survivin, cox-2 and cyclin D1
[8,9,10,11]. Activation of STAT3 and its target genes can lead to
cell-cycle progression, immune evasion, proangiogenesis, anti-
apoptotic effects, tumor invasion and metastasis [12,13], all of
which are typical characteristics of cancer [14]. Experiments have
shown that constitutively active STAT3 alone is able to induce
cellular transformation [15]. It is no surprise then that the
constitutive activation of the STAT3 pathway has been found in a
variety of cancers and is typically associated with a poorer
prognosis [9,12]. While STAT3 is critical during early embryo-
genesis, it is largely dispensable in the majority of adult cell types
which makes it an attractive therapeutic target [16,17,18].
The inhibition of the STAT3 signaling pathway in cancer cells,
using antisense oligonucleotides, RNA interference and dominant-
negative STAT3, has been shown to cause decreased cellular
growth and induce apoptosis [19,20,21,22,23]. Other indirect
methods of inhibiting STAT3 have also been examined. The
selective inhibition of the upstream tyrosine kinase, JAK2, can
prevent the phosphorylation and activation of STAT3 and several
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reported [24,25,26]. An intact SH2 domain is critical for STAT3
activation which makes it another reasonable target to disrupt
STAT3 signaling [27]. Peptide-based SH2 inhibitors have been
created,howevertheyhavelowinvivostability,poorcellpermeability
and the potential for immunogenicity [28,29]. In order to overcome
the shortcomings of peptide-based inhibitors, several non-peptide
small molecular SH2 inhibitors including Stattic, STA-21 and S3I-
201, have recently been reported [27,30,31].
Using a structure based computer design our collaborators
designed a non-peptide small molecule, termed LLL12 (Figure S1).
LLL12 was shown to bind directly to the phosphoryl tyrosine 705
(pY705) binding site of the STAT3 monomer on computer models
with docking simulation. Here we show that LLL12 inhibits
STAT3 phosphorylation, decreases cellular viability, downregu-
lates STAT3 target gene and induces apoptosis in medulloblas-
toma and glioblastoma cell lines.
Materials and Methods
Cell Culture
The medulloblastoma cell lines (Daoy, UW426, UW288-1, D341
and D283) were provided by Dr. Corey Raffel (The Research
Institute at Nationwide Children’s Hospital). The glioblastoma cell
linesU373 andU87D were providedbyDr.Sean Lawler(The Ohio
State University). The WI-38 (normal human lung fibroblasts) and
U87 (glioblastoma) cell lines were purchased from American Type
Culture Collection. HH (human hepatocytes) were purchased from
ScienCell and maintained in Hepatocyte Medium (ScienCell,
#5201) supplemented with hepatocyte supplement, 5% FBS and
1% streptomycin/penicillin solution. All other cells were main-
tained in 1X Dulbecco’s Modification of Eagle’s Medium (DMEM)
with 4.5 g/L, L-glutamine and sodium pyruvate (Mediatech, #10
013 CV) supplemented with 10% fetal bovine serum (FBS) (Sigma,
Table 1. IC50 values for medulloblastoma and glioblastoma
cell lines.
LLL12 LLL3 AG490 S3I-201
Daoy 2.79 82.81 20.9 .100
UW426 4.03 17.45 .100 .100
UW288-1 1.07 22.0 .100 .100
U87 1.99 12.9 .100 .100
U87D 5.98 14.8 .100 .100
The half-maximal inhibitory concentrations (IC50) calculated for LLL12 and other
STAT3/JAK2 inhibitors (mM) in medulloblastoma and glioblastoma cell lines.
Cellular proliferation was measured using a MTT Assay following 72 hours of
treatment.
doi:10.1371/journal.pone.0018820.t001
Figure 1. Western blot analysis of cells treated with LLL12. (A) Medulloblastoma cell lines and (B) glioblastoma cell lines which express
constitutively active STAT3 exhibit a decrease in p-STAT3 (Y705) following treatment with LLL12 for 6 and 24 hours respectively. No effect is seen on
other kinases such as p-AKTand pERK. Apoptosis is indicated by the cleavage of caspase 3. (C) Normal human lung fibroblasts (WI-38) and human
hepatocytes (HH) that do not express p-STAT3, did not show an induction of cleaved caspase-3.
doi:10.1371/journal.pone.0018820.g001
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in incubators set at 37 ˚C and aired with 5% CO2.
Synthesis of LLL12
LLL12 was synthesized in the laboratory of Dr. Pui-Kai Li as
previously described [32].
MTT Assay
Cells were seeded in 96-well plates in triplicate at a density of
3,000 cells per well and given 24 hours to adhere. Cells were then
treated with varying concentrations of the inhibitors in the
presence of 10% FBS. The cells were incubated for 72 hours at
37uC. 25 ml of MTT dye (Sigma, #M5655) was added to each
sample and incubated for 3.5 hours. After this, 100 ml of N,N-
dimethylformamide (Sigma, #D4551) solubilization solution was
added to each well. The absorbance at 450 nm was read the
following day. Half-Maximal inhibitory concentrations (IC50) were
determined using Sigma Plot 9.0 software (Systat Software Inc.).
CyQuant NF Cell Proliferation Assay
Cells were seeded in white, clear bottom 96-well plates in
triplicate at a density of 5,000 cells per well and allowed to adhere
Figure 2. Cell Death ELISA analysis following LLL12 treatment. (A) UW288-1, (B) U87, and (C) U87D exhibit a dose dependent increase in
apoptosis following treatment with LLL12 for either 18 hours (UW288-1) or 24 hours (U87 and U87D).
doi:10.1371/journal.pone.0018820.g002
Figure 3. RT-PCR Analysis of STAT3 target genes. LLL12 treatment was able to downregulate the expression of STAT3 target genes: Cyclin D1,
Survivin, Bcl-2 and Bcl-xL following 24 hours of treatment.
doi:10.1371/journal.pone.0018820.g003
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of LLL12 in the presence of 10% FBS and incubated at 37uC for
72 hours. The medium was then removed from the cells and
100 mL of 1X dye binding solution was added and plates were
incubated for one hour at 37uC. The fluorescence was then
measured with excitation at 485 nm and emission detection at
530 nm.
Western Blot Analysis
LLL12 and IL-6 (Invitrogen, #PHC0061) were both dissolved
in sterile dimethyl sulfoxide (DMSO) to make stock solutions of
20 mM and 10 ng/mL respectively. The cells were grown to semi-
confluency and then treated with LLL12 for either 6 or 24 hours.
For the IL-6 experiments, cells were pretreated with LLL12 for
2 hours and then treated with IL-6 for 30 minutes before being
harvested. For the IFN-c (Cell Signaling Tech., #8901) and LIF
(Invitrogen, #PHC9464) experiments, cells were pretreated with
LLL12 for 2 hours and then treated with either IFN-c or LIF for
24 hours. For western blots, 30 mg of total cell lysates were
resolved by SDS polyacrylamide gel electrophoresis (PAGE) and
transferred to PVDF membrane (GE Healthcare, #45-000-931).
These membranes were then blotted with phospho-specific
STAT3 antibody [Tyrosine 705] (#9131), phospho-independent
STAT3 antibody (#9132), cleaved caspase-3 [Asp175] antibody
(#9661), phospho-specific AKT [Serine 473] (#9271), phospho-
specific ERK [Threonine 202/Tyrosine 204] (#9101) and
GAPDH antibody (#2118). All antibodies were purchased from
Cell Signaling Tech. Membranes were analyzed with enhanced
chemiluminescence Plus reagents (GE Healthcare, #RPN5781)
and scanned with a Storm Scanner (Amersham Pharmacia
Biotech Inc.). Integrated densities of the bands in the western
blots were measured using Image J software (NIH). Densities were
individually normalized to GAPDH in each cell line and the
relative levels of p-STAT3, STAT3, cleaved caspase-3, p-AKT
and p-ERK were compared to the DMSO control, which was set
as 1.0.
Reverse-transcriptase PCR
Following 24 hours of treatment with LLL12, RNA was
collected from cells using a RNeasy Kit (Qiagen, #74104). cDNA
was generated from 500 ng of sample RNA using Omniscript RT
(Qiagen, #205111). Subsequently, 2 ml of cDNA was used for
PCR. PCR amplifications were performed as follows: 5 min at
94uC followed by 25 cycles of [30 sec at 94uC, 30 sec at 55uC,
30 sec at 72uC] and a final extension at 72uC for 5 min. The PCR
products were then run on 2% agarose gels, stained with ethidium
bromide and visualized under UV light.
Immunofluorescence
Cells were seeded on coverslips and grown until 80% confluent.
After either 6 or 24 hours of treatment with LLL12, cells were
fixed with ice-cold methanol for 30 minutes, washed and blocked
in 5% normal goat serum (Jackson ImmunoResearch Laborato-
ries, #005-000-121) in PBS for 1 hour at room temperature. The
coverslips were then incubated overnight at 4uC in a 1:100
dilution of cleaved caspase-3 (Asp175) antibody (Cell Signaling
Tech., #9661), washed and then incubated at room temperature
in a 1:1000 dilution of Alexa Fluor 594 conjugated goat anti-rabbit
IgG antibody (Invitrogen, #A-11037). Fluorescence staining was
examined using a Leica MZ 16FA inverted microscope (Leica
Figure 4. STAT3 DNA Binding Assay. Cells showed a dose-dependent decrease in STAT3 activation following treatment with LLL12 for either
18 hours (UW288-1) or 24 hours (u87 and U87D), indicating that LLL12 is able to effectively inhibit STAT3’s ability to bind DNA.
doi:10.1371/journal.pone.0018820.g004
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(Diagnostic Instruments Inc.).
Colony Formation
Cells were grown to semi-confluency in 10 cm plates and then
treated for either 6 hours or 24 hours. Cells were then trypsinized,
stained with trypan blue and counted. A low number of cells
(3,000 for UW288-1, 1,000 for U87 and 500 for U87D) were then
seeded on 15cm plates in duplicate and allowed to grow for two
weeks. Cells were then fixed in methanol for 30 minutes and
stained with 1% crystal violet dye.
Cell Death ELISA
Cells were seeded in 96 well plates at a density of 10
4 cells per
well and allowed to adhere overnight. They were then treated with
5 mM of LLL12 for either 18 or 24 hours. Cells were lysed directly
in the plate and 20 ml of lysate was transferred to a new plate and
the level of apoptosis was measured using the Cell Death
Detection ELISA
PLUS assay following the manufacturer’s protocol
(Roche, #11774425001).
DNA Binding Assay
Cells were grown to semi-confluency in 10 cm plates and then
treated with varying concentrations of LLL12 for either 18 or
24 hours. Cells were collected and the nuclear fraction was
extracted using a Nuclear Extract Kit (Active Motif, #40010)
according to the manufacturer’s protocol. 20 mg of nuclear extract
was used to analyze STAT3 activation using the TransAM
STAT3 Activation Assay (Active Motif, #45196) following the
manufacturer’s protocol. Samples were assayed in triplicate and
the error bars represent one standard deviation.
Wound Healing Assay
Cells were seeded in 6 well plates and allowed to grow until
confluent. They were then treated with varying amounts of LLL12
and the tip of a 1–10 ml disposable pipette tip was used to create a
wound by dragging it across the surface of the plate and dislodging
a line of cells. Cells were allowed to grow for 48 hours and images
were captured using a Leica MZ 16FA inverted microscope (Leica
Microsystems) with a 7.4 slider digital camera (Diagnostic
Instruments Inc.).
ELISA
To measure baseline levels of IL-6, cells were grown in 6 well
plates in DMEM supplemented with 10% FBS until ,70%
confluent. The media was then replaced and cells were allowed
to continue growing for 48 hours before the media was collected,
filter-sterilized and stored at 280uC. To examine the effect of
LLL12 on IL-6 secretion, cells were grown in 6 well plates until
,70% confluent and then the media was replaced and cells were
treated with either DMSO (control) or LLL12. Media was
collected at 8, 16 and 24 hours, filter-sterilized and stored at
280uC. IL-6 secretion was quantified using an IL-6 ELISA kit
(PeproTech, #900-K16) according to the manufacturer’s
Figure 5. Wound Healing Assay. Cells showed a dose-dependent decrease in their ability to migrate and heal the created wound following
treatment with LLL12.
doi:10.1371/journal.pone.0018820.g005
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secretion (RayBiotech Inc., #ELH-LIF-001). Samples were
assayed in triplicate and error bars represent one standard
deviation.
Results
LLL12 inhibits cellular viability/proliferation in human
medulloblastoma and glioblastoma cell lines
Cell Viability assays were run on several human medulloblas-
toma and glioblastoma cells lines which express elevated levels of
phosphorylated STAT3 (Figure 1A and 1B) in order to assess
LLL12’s inhibitory effects. After 72 hours of treatment, a dose-
dependent inhibition of cellular viability was seen. IC50 values
were calculated for LLL12 and other previously reported
inhibitors (Table 1); LLL3 [33] and S3I-201 [31], both STAT3
inhibitors, and AG490 [34], a JAK2 inhibitor. LLL12 was found
to be much more potent than the other inhibitors tested in the
inhibition of cell viability and proliferation. Cellular viability was
confirmed using a CyQuant NF assay, which measures cellular
content via fluorescent dye binding (data not shown). The
calculated IC50 values for LLL12 were very similar to those
determined by MTT, ranging from 0.7 mM to 3.68 mM.
LLL12 inhibits STAT3 phosphorylation and induces
apoptosis in human medulloblastoma and glioblastoma
cell lines
Several medulloblastoma and glioblastoma cell lines which
overexpress phosphorylated STAT3 (Daoy, UW426, UW288-1,
U87 and U87D) were used to evaluate the effects of LLL12 on
STAT3 phosphorylation and the induction of apoptosis. LLL12
inhibited the phosphorylation of STAT3 at tyrosine residue 705
(Y705) in all cell lines tested (Figure 1A and 1B). LLL12 did not
inhibit the phosphorylation of other kinases, such as ERK 1/2 and
AKT, indicating that LLL12 is specific for STAT3. LLL12 was
also able to induce apoptosis as evidenced by the cleavage of
caspase-3 (Figure 1A and 1B) which is consistent with the
inhibition of p-STAT3 (Y705) seen. LLL12 did not induce
apoptosis in normal human hepatocyte and lung fibroblast cell
lines, indicating that its toxicity is confined to cancer cells which
express p-STAT3 (Figure 1C). Using a Cell Death Detection
ELISA, which measures cytoplasmic histone-associated-DNA-
fragments, we saw a dose-dependent increase in apoptosis in
UW288-1, U87 and U87D cell lines after 18 and 24 hours of
treatment with LLL12 respectively (Figure 2A–2C). Cell death
through apoptosis was additionally confirmed in UW288-1, U87
and U87D cell lines using immunofluorescence to look for the
cleaved form of caspase 3 (Figure S2).
LLL12 inhibits the transcription of downstream STAT3
target genes
As previously mentioned, STAT3 activates the transcription of
a variety of genes responsible for cell cycle regulation, anti-
apoptotic effects and other hallmarks of cancer. Using Reverse
Transcriptase PCR, we examined LLL12’s effect on the activation
of these genes after 24 hours of treatment. We found that LLL12
inhibited the transcription of the STAT3 downstream target
genes, cyclin D1, survivin, Bcl-2, and Bcl-xL in medulloblastoma
and glioblastoma cell lines (Figure 3).
LLL12 is specific for STAT3 and does not inhibit STAT1
Two cell lines which express lower levels of p-STAT3 (Y705),
D283 (medulloblastoma) and U373 (glioblastoma), were used to
assess LLL12’s specificity. Cells were treated with IFN-c in order
Figure 6. Colony Formation Assay. Medulloblastoma and glioblastoma cell lines showed a decreased ability to form colonies following treatment
with LLL12 for either 6 hours (UW288-1) or 24 hours (U87 and U87D).
doi:10.1371/journal.pone.0018820.g006
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with LLL12. LLL12 was not able to block the activation of
STAT1, indicating that it is specific for STAT3 (Figure S3).
LLL12 inhibits STAT3 DNA binding activity
We examined LLL12’s effect on DNA binding activity in order
to assess the drug’s ability to inhibit STAT3 signaling. Using an
ELISA-based assay, we measured the DNA binding ability of
STAT3 in the cell lines UW288-1, U87 and U87D. We found a
dose-dependent decrease in STAT3 binding (Figure 4). This
method was previously utilized in our lab to examine LLL12’s
effect on STAT1 DNA binding and we found no inhibition of
STAT1 DNA binding activity, indicating once again that LLL12
is a specific inhibitor of STAT3 [32].
Wound Healing and colony formation are inhibited in the
presence of LLL12
Many cellular processes, such as proliferation, angiogenesis,
invasion and migration are common to both wound healing and
cancer [35] and these similarities have given rise to the concept
that tumors are ‘‘wounds that do not heal’’ [36]. In order to assess
LLL12’s ability to inhibit wound healing, a wound healing assay
was performed on UW288-1, U87 and U87D cells. After the
creation of a wound, cells were treated with varying concentrations
of LLL12 and allowed 48 hours to proliferate and migrate into the
wound. Treatment with LLL12 resulted in a decreased ability for
cells to migrate and heal the created wound (Figure 5).
We also examined the ability of the cells to recover after
treatment with LLL12 by performing a colony formation assay.
The cell lines UW288-1, U87 and U87D were treated with LLL12
for 4 and 24 hours respectively and then the same number of
living cells was reseeded at very low cell densities and allowed to
grow for 2 weeks. Cells were then fixed and stained and the plates
were scanned. The cancer cells showed a decreased ability to
recover and form colonies following treatment with LLL12
(Figure 6).
LLL12 is able to inhibit the secretion of IL-6 and LIF in
Medulloblastoma and Glioblastoma cell lines
IL-6 is a pleiotropic cytokine which has been shown to be
overexpressed in response to infection, injury and inflammation.
Many tumor cells have been found to produce excess amounts of
IL-6 or alternatively, express an IL-6 receptor which allows
them to respond to IL-6 produced by the tumor microenviron-
ment [37]. The binding of IL-6 to its receptor leads to the
activation of the Janus kinase family which in turn phosphor-
ylate STAT3 [38]. Using an ELISA, we measured the amount of
IL-6 secreted by our medulloblastoma and glioblastoma cell
lines. We found that UW288-1, UW426 and U87D secreted
measurably higher levels of IL-6 than the other cell lines tested
(Figure 7). Next we wanted to see whether or not LLL12 could
block the secretion of IL-6 since the gene encoding it is one of
STAT3’s targets [39]. Cells were treated with LLL12 and their
media was collected after 8, 16 and 24 hours for analysis. LLL12
was able to inhibit the secretion of IL-6 in UW288-1, U87 and
U87D cells as early as 8 hours after treatment and the decrease
was still seen at 24 hours post treatment (Figure 8A–8C). We
also saw a decrease in the expression of IL-6 mRNA following
LLL12 treatment (Figure 8D). We also looked at LLL12’s ability
to inhibit the induction of p-STAT3 following IL-6 treatment in
cell lines that do not express activated STAT3. Cells were
pretreated with LLL12 for 2 hours and then IL-6 was added for
30 minutes. We found that LLL12 was able to completely block
the phosphorylation of STAT3 caused by IL-6 treatment
(Figure 9A and 9B).
We also wanted to examine the secretion of leukemia inhibitory
factor (LIF) because it is an IL-6 family member [40] that has been
shown to be constitutively expressed both in vitro and in vivo in
medulloblastoma cells [41]. We found elevated levels of LIF in
UW288-1 and UW426 cells and treatment with LLL12 was able
to inhibit LIF secretion and decrease the expression of LIF mRNA
(Figure S4A–4C). We also wanted to see if LLL12 could block the
activation of STAT3 by LIF. Cells were pretreated with LLL12 for
2 hours and then treated with LIF for 24 hours. LLL12 was found
to be able to inhibit the phosphorylation of STAT3 caused by LIF
treatment but had no effect on the phosphorylation of AKT or
ERK (Figure 9C).
Discussion
Despite several new treatment options, the prognosis for
patients diagnosed with glioblastoma remains poor with a median
survival of 15 months for glioblastoma patients [7] and although
treatment for medulloblastoma has proven more effective,
resulting in a 5-year survival of 70–80% [42], the long term
effects can be severe [2]. More effective and less toxic treatment
Figure 7. IL-6 secretion in medulloblastoma and glioblastoma
cell lines. IL-6 secretion was measured by ELISA after 48 hours. The cell
lines UW288-1, UW426 and U87D secreted elevated levels of IL-6.
doi:10.1371/journal.pone.0018820.g007
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combat these devastating tumors. Our collaborators developed a
non-peptide small molecule inhibitor of STAT3, LLL12, which
has shown promising results in the treatment of several types of
cancer [32].
We examined the effects of LLL12 on medulloblastoma and
glioblastoma cell lines which express phosphorylated STAT3.
We found that LLL12 is able to inhibit cell viability, decrease
STAT3 target gene expression, decrease STAT3 DNA binding,
inhibit wound healing and colony formation and induce
apoptosis. LLL12 did not have any effect on the phosphorylation
of ERK or AKT, and it did not inhibit STAT1 activation caused
by IFN-c treatment, indicating that it is a specific inhibitor of
STAT3. The cytokine IL-6 has been found to be a major
contributor to the tumor microenvironment and many tumors
have been found to express high levels of IL-6 or an IL-6
receptor [37,43]. We found that UW288-1, UW426 and U87D
secrete high levels of IL-6 and that LLL12 was able to decrease
IL-6 expression and secretion. This is significant because while
not all tumors overexpress activated STAT3, IL-6 secreted in the
microenvironment may be able to activate STAT3 and LLL12
can block that activation and inhibit the pro-tumorigenic effects
of STAT3. We also examined the ability of LLL12 to inhibit
STAT3 activation caused by LIF. LIF has been shown to be
constitutively expressed in medulloblastoma cells [41] and we
found high levels of LIF secreted in UW288-1 and UW426 cells.
Treatment with LLL12 was able to block the secretion of LIF
and downregulate the expression of LIF, however the exact
mechanism is unclear since LIF is not a target gene of STAT3
like IL-6.
Figure 8. LLL12 inhibition of IL-6 secretion. (A–C) Cells were treated with LLL12 for 8, 16 and 24 hours and IL-6 levels were measured using an
ELISA. IL-6 secretion was reduced at all three time points. (D) LLL12 inhibits the expression of IL-6 mRNA.
doi:10.1371/journal.pone.0018820.g008
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using parameters such as molecular weight, cell permeability,
solubility, and metabolic stability and its toxicity, absorption,
metabolism and excretion were also measured. LLL12 was shown
to have decent drug-like properties which warrant further
investigation [32].
One of the problems encountered when trying to treat brain
tumors is drug delivery across the blood brain barrier (BBB). There
have been many new techniques and strategies employed to disrupt
the BBB or to deliver drugs across the barrier including: transient
osmotic BBB disruption (BBBD), biochemical BBBD, ultrasound-
mediated BBBD, implanted polymers, intra-cavitary delivery
systemsandconvection-enhanceddelivery[44]butthesetechniques
need to be paired with novel therapies in order to truly gauge the
effectiveness of new treatments. We have shown LLL12 to be an
effective inhibitor of STAT3 and it has been shown to reduce to
reduce tumor size in vivo [32] but it remains to be seen whether or
not LLL12, in conjunction with available BBBD methods, can
effectively cross the barrier and suppress tumor growth. Additional
studies need to be done employing more advanced mouse models
and BBBD techniques to further evaluate LLL12’s effectiveness
against glioblastoma and medulloblastoma but our early findings
indicate that LLL12 merits further investigation.
Supporting Information
Figure S1 Chemical Structure of LLL12.
(TIF)
Figure S2 Immunofluorescence for cleaved caspase-3.
Cells were treated with LLL12 for either 6 (UW288-1) or 24 hours
(U87 and U87D) and stained for cleaved caspase-3. LLL12
induced apoptosis in all cell lines as evidenced by the presence of
cleaved caspase-3.
(TIF)
Figure S3 LLL12 does not inhibit IFN-c induced STAT1
activation. D283 and U373 cells were pre-treated with LLL12
for 2 hours and then treated with IFN-c for 24 hours. IFN-c
induced the phosphorylation of STAT1 but pre-treatment with
LLL12 was not able to inhibit this induction, indicating it is
specific for STAT3.
(TIF)
Figure 9. LLL12 inhibits IL-6 and LIF induced STAT3 phosphorylation. (A) D283 and (B) U373 cells were pretreated with LLL12 for 2 hours
and then treated with IL-6 for 30 minutes to induce p-STAT3. LLL12 was able to block STAT3 activation by IL-6 and did not have an effect of p-AKT or
p-ERK. (C) D283 cells were pretreated with LLL12 for 2 hours and then treated with LIF for 24 hours to activate STAT3. LLL12 was able to inhibit the
phosphorylation of STAT3 induced by LIF and did not inhibit p-AKT or p-ERK expression.
doi:10.1371/journal.pone.0018820.g009
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(A) ELISA analysis showed elevated levels of LIF in UW288-1 and
UW426 cell lines. (B) LLL12 was able to block the secretion of LIF
in UW426 cells. (C) LLL12 was able to downregulate the
expression of LIF mRNA.
(TIF)
Acknowledgments
We would like to thank Dr. Corey Raffel for providing us with the
medulloblastoma cell lines and Dr. Sean Lawler for the U87D cell line.
Author Contributions
Conceived and designed the experiments: SB JL. Performed the
experiments: SB. Analyzed the data: SB JL. Contributed reagents/
materials/analysis tools: SB JL CLL P-KL. Wrote the paper: SB.
References
1. CBTRUS, Central Brain Tumor Registry of the United States (2007–2008)
Primary brain tumors of the United States, Statistical Report (2000–2004), Years
of Data Collected.
2. Huse JT, Holland EC (2010) Targeting brain cancer: advances in the molecular
pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10:
319–331.
3. Mueller S, Chang S (2009) Pediatric brain tumors: current treatment strategies
and future therapeutic approaches. Neurotherapeutics 6: 570–586.
4. Collins VP (1998) Gliomas. Cancer Surv 32: 37–51.
5. Dohrmann GJ, Farwell JR, Flannery JT (1976) Glioblastoma multiforme in
children. J Neurosurg 44: 442–448.
6. Nicholas MK (2007) Glioblastoma multiforme: evidence-based approach to
therapy. Expert Rev Anticancer Ther 7: S23–27.
7. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:
492–507.
8. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, et al. (2006) c-myc
overexpression causes anaplasia in medulloblastoma. Cancer Res 66: 673–681.
9. Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human
tumors provides novel molecular targets for therapeutic intervention. Clin
Cancer Res 8: 945–954.
10. Pizem J, Cort A, Zadravec-Zaletel L, Popovic M (2005) Survivin is a negative
prognostic marker in medulloblastoma. Neuropathol Appl Neurobiol 31:
422–428.
11. Rosen DG, Mercado-Uribe I, Yang G, Bast RC, Jr., Amin HM, et al. (2006)
The role of constitutively active signal transducer and activator of transcription 3
in ovarian tumorigenesis and prognosis. Cancer 107: 2730–2740.
12. Yu H, Jove R (2004) The STATs of cancer—new molecular targets come of age.
Nat Rev Cancer 4: 97–105.
13. Bowman T, Garcia R, Turkson J, Jove R (2000) STATs in oncogenesis.
Oncogene 19: 2474–2488.
14. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70.
15. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al. (1999)
Stat3 as an oncogene. Cell 98: 295–303.
16. Takeda K, Noguchi K, Shi W, Tanaka T, Matsumoto M, et al. (1997) Targeted
disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl
Acad Sci U S A 94: 3801–3804.
17. Akira S (2000) Roles of STAT3 defined by tissue-specific gene targeting.
Oncogene 19: 2607–2611.
18. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, et al. (2006)
Targeting signal-transducer-and-activator-of-transcription-3 for prevention and
therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091:
151–169.
19. Aoki Y, Feldman GM, Tosato G (2003) Inhibition of STAT3 signaling induces
apoptosis and decreases survivin expression in primary effusion lymphoma.
Blood 101: 1535–1542.
20. Burke WM, Jin X, Lin HJ, Huang M, Liu R, et al. (2001) Inhibition of
constitutively active Stat3 suppresses growth of human ovarian and breast cancer
cells. Oncogene 20: 7925–7934.
21. Kaptein A, Paillard V, Saunders M (1996) Dominant negative stat3 mutant
inhibits interleukin-6-induced Jak-STAT signal transduction. J Biol Chem 271:
5961–5964.
22. Calvin D NS, Buettner R, Sekharam M, Torres-Roca J, Jove R (2003) Inhibition
of STAT3 activity with STAT3 antisense oligonucleotide (STAT3-ASO)
enhances radiation-induced apoptosis in DU145 prostate cancer cells.
Int J Radiat Oncol Biol Phys 57: S297.
23. Ling X, Arlinghaus RB (2005) Knockdown of STAT3 expression by RNA
interference inhibits the induction of breast tumors in immunocompetent mice.
Cancer Res 65: 2532–2536.
24. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, et al. (1996) Inhibition
of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645–648.
25. Duan Z, Bradner JE, Greenberg E, Levine R, Foster R, et al. (2006) SD-1029
inhibits signal transducer and activator of transcription 3 nuclear translocation.
Clin Cancer Res 12: 6844–6852.
26. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, et al. (2007) A novel
inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells
both in vitro and in vivo. Oncogene 26: 2435–2444.
27. Song H, Wang R, Wang S, Lin J (2005) A low-molecular-weight compound
discovered through virtual database screening inhibits Stat3 function in breast
cancer cells. Proc Natl Acad Sci U S A 102: 4700–4705.
28. Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, et al. (2001) Phosphotyrosyl
peptides block Stat3-mediated DNA binding activity, gene regulation, and cell
transformation. J Biol Chem 276: 45443–45455.
29. Coleman DRt, Ren Z, Mandal PK, Cameron AG, Dyer GA, et al. (2005)
Investigation of the binding determinants of phosphopeptides targeted to the
SRC homology 2 domain of the signal transducer and activator of transcription
3. Development of a high-affinity peptide inhibitor. J Med Chem 48:
6661–6670.
30. Schust J, Sperl B, Hollis A, Mayer TU, Berg T (2006) Stattic: a small-molecule
inhibitor of STAT3 activation and dimerization. Chem Biol 13: 1235–1242.
31. Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, et al. (2007)
Selective chemical probe inhibitor of Stat3, identified through structure-based
virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A 104:
7391–7396.
32. Lin L, Hutzen B, Li PK, Ball S, Zuo M, et al. (2010) A novel small molecule,
LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent
growth-suppressive activity in human cancer cells. Neoplasia 12: 39–50.
33. Bhasin D, Cisek K, Pandharkar T, Regan N, Li C, et al. (2008) Design,
synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem
Lett 18: 391–395.
34. Miyamoto N, Sugita K, Goi K, Inukai T, Lijima K, et al. (2001) The JAK2
inhibitor AG490 predominantly abrogates the growth of human B-precursor
leukemic cells with 11q23 translocation or Philadelphia chromosome. Leukemia
15: 1758–1768.
35. Dauer DJ, Ferraro B, Song L, Yu B, Mora L, et al. (2005) Stat3 regulates genes
common to both wound healing and cancer. Oncogene 24: 3397–3408.
36. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor
stroma generation and wound healing. N Engl J Med 315: 1650–1659.
37. Scheller J, Rose-John S (2006) Interleukin-6 and its receptor: from bench to
bedside. Med Microbiol Immunol 195: 173–183.
38. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, et al.
(2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation.
Biochem J 374: 1–20.
39. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a
leading role for STAT3. Nat Rev Cancer 9: 798–809.
40. Zhang L, Badgwell DB, Bevers JJ, 3rd, Schlessinger K, Murray PJ, et al. (2006)
IL-6 signaling via the STAT3/SOCS3 pathway: functional analysis of the
conserved STAT3 N-domain. Mol Cell Biochem 288: 179–189.
41. Liu J, Li JW, Gang Y, Guo L, Li H (1999) Expression of leukemia-inhibitory
factor as an autocrinal growth factor in human medulloblastomas. J Cancer Res
Clin Oncol 125: 475–480.
42. Gilbertson RJ (2004) Medulloblastoma: signalling a change in treatment. Lancet
Oncol 5: 209–218.
43. Ara T, Declerck YA (2010) Interleukin-6 in bone metastasis and cancer
progression. Eur J Cancer 46: 1223–1231.
44. Bidros DS, Vogelbaum MA (2009) Novel Drug Delivery Strategies in Neuro-
Oncology. Neurotherapeutics 6: 539–546.
LLL12 Inhibits p-STAT3 in Brain Tumors
PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18820